Johan A F Koekkoek1, Linda Dirven2, Jan J Heimans2, Tjeerd J Postma2, Maaike J Vos3, Jaap C Reijneveld2, Martin J B Taphoorn1. 1. Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands Department of Neurology, Medical Centre Haaglanden, The Hague, The Netherlands. 2. Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands. 3. Department of Neurology, Medical Centre Haaglanden, The Hague, The Netherlands.
Abstract
BACKGROUND: Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled. Besides antiepileptic drugs, antitumour treatment might contribute to a reduction in seizure frequency. The aim of this study was to determine the effect of temozolomide (TMZ) chemotherapy on seizure frequency, to identify factors associated with post-treatment seizure reduction and to analyse the prognostic value of seizure reduction for survival. METHODS: We retrospectively reviewed adult patients with supratentorial LGG and epilepsy who received chemotherapy with TMZ as initial treatment or for progressive disease in two hospitals (VUmc Amsterdam; MCH The Hague) between 2002 and 2012. RESULTS: We identified 104 patients with LGG with epilepsy who had received TMZ. Uncontrolled epilepsy in the 3 months preceding chemotherapy was present in 66 of 104 (63.5%) patients. A ≥ 50% reduction in seizure frequency after 6 months occurred in 29 of 66 (43.9%) patients. Focal symptoms at presentation (OR 6.55; 95% CI 1.45 to 32.77; p = 0.015) appeared to be positively associated with seizure reduction. Seizure reduction was an independent prognostic factor for progression-free survival (HR 0.32; 95% CI 0.15 to 0.66; p = 0.002) and overall survival (HR 0.33; 95% CI 0.14 to 0.79; p = 0.013), along with a histological diagnosis of oligodendroglioma (HR 0.38; 95% CI 0.17 to 0.86; p = 0.021). Objective responses on MRI were similar for patients with and without seizure reduction. CONCLUSIONS: TMZ may contribute to an important reduction in seizure frequency in patients with LGG. Seizure reduction following TMZ treatment has prognostic significance and may serve as an important clinical outcome measure in patients with LGG. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled. Besides antiepileptic drugs, antitumour treatment might contribute to a reduction in seizure frequency. The aim of this study was to determine the effect of temozolomide (TMZ) chemotherapy on seizure frequency, to identify factors associated with post-treatment seizure reduction and to analyse the prognostic value of seizure reduction for survival. METHODS: We retrospectively reviewed adult patients with supratentorial LGG and epilepsy who received chemotherapy with TMZ as initial treatment or for progressive disease in two hospitals (VUmc Amsterdam; MCH The Hague) between 2002 and 2012. RESULTS: We identified 104 patients with LGG with epilepsy who had received TMZ. Uncontrolled epilepsy in the 3 months preceding chemotherapy was present in 66 of 104 (63.5%) patients. A ≥ 50% reduction in seizure frequency after 6 months occurred in 29 of 66 (43.9%) patients. Focal symptoms at presentation (OR 6.55; 95% CI 1.45 to 32.77; p = 0.015) appeared to be positively associated with seizure reduction. Seizure reduction was an independent prognostic factor for progression-free survival (HR 0.32; 95% CI 0.15 to 0.66; p = 0.002) and overall survival (HR 0.33; 95% CI 0.14 to 0.79; p = 0.013), along with a histological diagnosis of oligodendroglioma (HR 0.38; 95% CI 0.17 to 0.86; p = 0.021). Objective responses on MRI were similar for patients with and without seizure reduction. CONCLUSIONS:TMZ may contribute to an important reduction in seizure frequency in patients with LGG. Seizure reduction following TMZ treatment has prognostic significance and may serve as an important clinical outcome measure in patients with LGG. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello Journal: Acta Neuropathol Date: 2015-02-28 Impact factor: 17.088
Authors: Johan A F Koekkoek; Melissa Kerkhof; Linda Dirven; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neuro Oncol Date: 2015-03-25 Impact factor: 12.300
Authors: Seth A Climans; Alba A Brandes; J Gregory Cairncross; Keyue Ding; Michael Fay; Normand Laperriere; Johan Menten; Ryo Nishikawa; Christopher J O'Callaghan; James R Perry; Claire Phillips; Wilson Roa; Wolfgang Wick; Chad Winch; Warren P Mason Journal: J Neurooncol Date: 2020-07-06 Impact factor: 4.130
Authors: Edward K Avila; Marc Chamberlain; David Schiff; Jaap C Reijneveld; Terri S Armstrong; Roberta Ruda; Patrick Y Wen; Michael Weller; Johan A F Koekkoek; Sandeep Mittal; Yoshiki Arakawa; Ali Choucair; Jorge Gonzalez-Martinez; David R MacDonald; Ryo Nishikawa; Aashit Shah; Charles J Vecht; Paula Warren; Martin J van den Bent; Lisa M DeAngelis Journal: Neuro Oncol Date: 2016-09-20 Impact factor: 12.300